Bortezomib for AL amyloidosis: Moving forward

Blood

Volumn 118, Issue 4, 2011, Pages 827-828

  Dimopoulos, Meletios A ^a   Kastritis, Efstathios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID PROTEIN; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; PROTEASOME;

ABSORPTION; AMYLOIDOSIS; APOPTOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG MEGADOSE; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; INTRACELLULAR SPACE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN SYNTHESIS; PROTEIN TARGETING; REMISSION; SURVIVAL RATE;

EID: 79960969679     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-05-355115     Document Type: Article

References (11)

1. Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Blade J, et al. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011;118(4):865-873.
2. Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520-2530.
3. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583-596. (Pubitemid 36951371)
4. Comenzo RL. How I treat amyloidosis. Blood. 2009;114(15):3147-3157.
5. Sitia R, Palladini G, Merlini G. Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica. 2007;92(10):1302-1307. (Pubitemid 350144146)
6. Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113(13):3040-3049.
7. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica. 2007;92(10):1351-1358. (Pubitemid 350144152)
8. Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica. 2008;93(2):295-298. (Pubitemid 351397721)
9. Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, et al. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009;114(8):1489-9147.
10. Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28(6):1031-1037.
11. Kastritis E, Roussou M, Migkou M, Gavriatopoulou M, Pamboukas C, Delimpassi S, et al. Long-term follow-up of the combination of bortezomib with dexamethasone as initial treatment for AL amyloidosis [abstract]. ASH Annual Meeting Abstracts. 2010;116(21):3048.